Effects of the Part D Senior Savings Model on racial and ethnic disparities in healthcare costs.

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Current Medical Research and Opinion Pub Date : 2025-03-01 Epub Date: 2025-03-31 DOI:10.1080/03007995.2025.2479780
Chi Chun Steve Tsang, Xiangjun Zhang, Ashley Ellis, Jessie Jiaqi Zeng, Junling Wang
{"title":"Effects of the Part D Senior Savings Model on racial and ethnic disparities in healthcare costs.","authors":"Chi Chun Steve Tsang, Xiangjun Zhang, Ashley Ellis, Jessie Jiaqi Zeng, Junling Wang","doi":"10.1080/03007995.2025.2479780","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The Centers for Medicare & Medicaid Services tested the Part D Senior Savings Model (\"PDSS Model\") in 2021, capping monthly out-of-pocket (OOP) insulin costs at $35. Diabetes disproportionately affects racial/ethnic minorities compared to their non-Hispanic White (White) counterparts, so this study compared the changes in racial/ethnic disparities in healthcare costs among insulin users between Medicare and non-Medicare populations in 2021.</p><p><strong>Methods: </strong>This study analyzed the Medical Expenditure Panel Survey (2020-2021). The intervention group comprised Medicare beneficiaries aged ≥65, while the comparison group included a near-elderly non-Medicare population. The study outcomes included annual OOP/total costs in 2021 dollars for insulin, medication, health services (medical), and overall healthcare. A difference-in-differences-in-differences approach was employed to assess the PDSS Model's effects between White and each racial/ethnic minority group.</p><p><strong>Results: </strong>The weighted sample included 1,056,386 insulin users (53.89% intervention). In 2020, among the intervention group, non-Hispanic Black (Black) and Hispanic had similar or higher insulin costs than White patients. Black-White differences in OOP insulin costs were lowered more among the intervention group (cost ratio [CR] = 0.12, 95% confidence interval = 0.06-0.22) than the comparison group. Black-White differences in OOP costs for medication, health services, and overall healthcare widened more among the intervention group by 61-64%. These patterns were not seen for other racial/ethnic disparities.</p><p><strong>Conclusions: </strong>Among insulin users, Black may have benefited more from the PDSS Model than White patients, which may be associated with enhanced insulin access and lower needs for other healthcare. Future studies should examine the long-term and heterogeneous impact of the PDSS Model.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"431-440"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12018076/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2479780","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The Centers for Medicare & Medicaid Services tested the Part D Senior Savings Model ("PDSS Model") in 2021, capping monthly out-of-pocket (OOP) insulin costs at $35. Diabetes disproportionately affects racial/ethnic minorities compared to their non-Hispanic White (White) counterparts, so this study compared the changes in racial/ethnic disparities in healthcare costs among insulin users between Medicare and non-Medicare populations in 2021.

Methods: This study analyzed the Medical Expenditure Panel Survey (2020-2021). The intervention group comprised Medicare beneficiaries aged ≥65, while the comparison group included a near-elderly non-Medicare population. The study outcomes included annual OOP/total costs in 2021 dollars for insulin, medication, health services (medical), and overall healthcare. A difference-in-differences-in-differences approach was employed to assess the PDSS Model's effects between White and each racial/ethnic minority group.

Results: The weighted sample included 1,056,386 insulin users (53.89% intervention). In 2020, among the intervention group, non-Hispanic Black (Black) and Hispanic had similar or higher insulin costs than White patients. Black-White differences in OOP insulin costs were lowered more among the intervention group (cost ratio [CR] = 0.12, 95% confidence interval = 0.06-0.22) than the comparison group. Black-White differences in OOP costs for medication, health services, and overall healthcare widened more among the intervention group by 61-64%. These patterns were not seen for other racial/ethnic disparities.

Conclusions: Among insulin users, Black may have benefited more from the PDSS Model than White patients, which may be associated with enhanced insulin access and lower needs for other healthcare. Future studies should examine the long-term and heterogeneous impact of the PDSS Model.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
D部分老年人储蓄模型对医疗费用种族差异的影响。
目标:医疗保险和医疗补助服务中心在2021年测试了D部分高级储蓄模式(“PDSS模式”),每月自付(OOP)胰岛素费用上限为35美元。与非西班牙裔白人(白人)相比,糖尿病对少数种族/族裔的影响不成比例,因此本研究比较了2021年医疗保险和非医疗保险人群中胰岛素使用者的种族/族裔差异的变化。方法:本研究对《2020-2021年医疗费用面板调查》进行分析。干预组包括年龄≥65岁的Medicare受益人,而对照组包括接近老年的非Medicare人群。研究结果包括胰岛素、药物、健康服务(医疗)和整体医疗保健的年度OOP/总成本(以2021美元计)。采用差异中差异(DDD)方法评估PDSS模型在白人和各种族/少数民族群体之间的效果。结果:加权样本包括1,056,386名胰岛素使用者,干预率为53.89%。2020年,在干预组中,非西班牙裔黑人(Black)和西班牙裔患者的胰岛素成本与白人患者相似或更高。干预组OOP胰岛素成本的黑白差异明显低于对照组(成本比[CR] = 0.12, 95%可信区间= 0.06-0.22)。在药物、卫生服务和整体医疗保健方面,黑人和白人在OOP成本方面的差异在干预组中扩大了61%-64%。这些模式在其他种族/民族差异中没有出现。结论:在胰岛素使用者中,黑人可能比白人患者从PDSS模型中获益更多,这可能与胰岛素获取增加和其他医疗保健需求降低有关。未来的研究应该检验PDSS模型的长期和异质性影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
期刊最新文献
Risk of liver and cardiovascular outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH): a retrospective cohort study. A randomized double-blind placebo-controlled trial of oliceridine, a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. Clinical biomarker potential of spectrin breakdown degradation products: a systematic review. Contemporary approaches to perioperative anticoagulant management in surgical patients: a literature review. Integrating epic aura and shared decision-making to improve colorectal cancer screening participation at the University of Washington Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1